PUBLIC HEALTH STRATEGIES FOR THE EARLY DIAGNOSIS OF HERPES ZOSTER IN THE ELDERLY
DOI:
https://doi.org/10.56238/sevened2026.016-039Keywords:
Herpes Zoster, Early Diagnosis, Aged, Neuralgia, Postherpetic, VaccinationAbstract
Introduction: Herpes Zoster (HZ) results from the reactivation of the latent varicella-zoster virus in sensory ganglia, predominantly affecting elderly individuals from 50 years of age onward, with an incidence of 3.9 to 11.8 cases per 1,000 person-years in those over 65. Early diagnosis is challenging due to a painful prodromal phase that precedes the characteristic vesicular rash, delaying antiviral therapy, which is ideally initiated within the first 72 hours. Objective: To analyze scientific evidence regarding public health strategies aimed at the early diagnosis of HZ in the elderly. Methods: A narrative literature review was conducted using the PubMed database, with the descriptors “Herpes Zoster” and “Diagnosis,” combined through the Boolean operators AND/OR according to MeSH terminology, including articles from the last five years, in Portuguese or English, with full text available. Results: Recognition of sentinel signs, such as Hutchinson’s sign, and the use of PCR in atypical cases (sensitivity above 95%) are essential for timely diagnosis. Diagnostic delay favors complications such as post-herpetic neuralgia, Herpes Zoster Ophthalmicus, and impairment of functional capacity and autonomy in the elderly. The adjuvanted recombinant vaccine (Shingrix) demonstrated 97.2% efficacy in preventing HZ and 91.2% against post-herpetic neuralgia, in addition to an association with a 20% reduction in dementia risk. Conclusion: The integration of early diagnostic competence and expanded vaccine coverage constitutes an essential strategy for reducing the physical and cognitive morbidity associated with HZ, promoting healthy aging and the sustainability of health systems.
References
BAGATTINI, A. M. et al. Health resource use and epidemiologic profile of herpes zoster outpatients aged 50 years or older: a modified Delphi consensus panel in Brazil. Brazilian Journal of Infectious Diseases, v. 29, p. 104560, 2025.
COHEN, E. J.; JENG, B. H. Herpes zoster: a brief definitive review. Cornea, v. 40, n. 8, p. 943-949, ago. 2021.
EYTING, M. et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature, v. 641, p. 438-446, maio 2025.
LIM, D. Z. J. et al. Herpes zoster and post-herpetic neuralgia: diagnosis, treatment, and vaccination strategies. Pathogens, v. 13, n. 7, p. 596, jul. 2024.
LIMA, F. et al. Análise epidemiológica do varicela-zoster no Brasil entre 2012 e 2017. Revista Multidisciplinar de Educação e Meio Ambiente, v. 1, n. 1, 2020.
OLIVEIRA, A. et al. Análise epidemiológica das internações e óbitos por infecção do vírus varicela-zoster no Brasil. Brazilian Journal of Implantology and Health Sciences, v. 6, n. 4, p. 271-280, 2024.
PATIL, A.; GOLDUST, M.; WOLLINA, U. Herpes zoster: a review of clinical manifestations and management. Viruses, v. 14, n. 2, p. 192, jan. 2022.
SHAH, S. et al. Herpes zoster vaccination and the risk of dementia: a systematic review and meta-analysis. Brain and Behavior, v. 14, n. 3, e3415, mar. 2024.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.